Yassen A - Search Results

1

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

Strougo A, Eissing T, Yassen A, Willmann S, Danhof M, Freijer J. Strougo A, et al. Among authors: yassen a. J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):195-203. doi: 10.1007/s10928-012-9241-9. Epub 2012 Feb 5. J Pharmacokinet Pharmacodyn. 2012. PMID: 22311388 Free PMC article.

2

Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.

Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, Dahan A. Yassen A, et al. Clin Pharmacol Ther. 2007 Jan;81(1):50-8. doi: 10.1038/sj.clpt.6100025. Clin Pharmacol Ther. 2007. PMID: 17185999 Clinical Trial.

3

Response to letter to the editor from Dr. Mahmood: Original publication: "Predicting the 'first dose in children' of CYP3A-metabolized drugs: evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages".

Strougo A, Yassen A, Danhof M, Freijer J. Strougo A, et al. Among authors: yassen a. J Clin Pharmacol. 2015 Jun;55(6):721. doi: 10.1002/jcph.490. J Clin Pharmacol. 2015. PMID: 25943827 No abstract available.

4

Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Yassen A, Olofsen E, van Dorp E, Sarton E, Teppema L, Danhof M, Dahan A. Yassen A, et al. Clin Pharmacokinet. 2007;46(11):965-80. doi: 10.2165/00003088-200746110-00004. Clin Pharmacokinet. 2007. PMID: 17922561 Clinical Trial.

5

Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.

Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Yassen A, et al. Pharm Res. 2008 Jan;25(1):183-93. doi: 10.1007/s11095-007-9440-z. Epub 2007 Oct 4. Pharm Res. 2008. PMID: 17914664 Free PMC article.

6

Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.

Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Yassen A, et al. Clin Pharmacokinet. 2007;46(5):433-47. doi: 10.2165/00003088-200746050-00005. Clin Pharmacokinet. 2007. PMID: 17465641

7

Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.

Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Yassen A, et al. J Pharmacol Exp Ther. 2007 May;321(2):598-607. doi: 10.1124/jpet.106.115972. Epub 2007 Feb 5. J Pharmacol Exp Ther. 2007. PMID: 17283225

8

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.

Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Yassen A, et al. J Pharmacol Exp Ther. 2006 Nov;319(2):682-92. doi: 10.1124/jpet.106.107953. Epub 2006 Jul 19. J Pharmacol Exp Ther. 2006. PMID: 16855177

9

Naloxone reversal of buprenorphine-induced respiratory depression.

van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, Danhof M, Dahan A. van Dorp E, et al. Among authors: yassen a. Anesthesiology. 2006 Jul;105(1):51-7. doi: 10.1097/00000542-200607000-00012. Anesthesiology. 2006. PMID: 16809994 Free article. Clinical Trial.

10

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.

Yassen A, Olofsen E, Dahan A, Danhof M. Yassen A, et al. J Pharmacol Exp Ther. 2005 Jun;313(3):1136-49. doi: 10.1124/jpet.104.082560. Epub 2005 Feb 8. J Pharmacol Exp Ther. 2005. PMID: 15701707

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results